Product Description
Mechanisms of Action: LptD Binder
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Polyphor
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Pneumonia, Bacterial|Pneumonia|Pneumonia, Ventilator-Associated
Phase 2: Bronchiectasis|Respiratory Tract Infections|Pseudomonas Infections|Pneumonia, Ventilator-Associated|Pneumonia|Cystic Fibrosis
Phase 1: Healthy Volunteers|Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2018-001159-11 | P3 |
Completed |
Pneumonia |
2019-07-17 |
|
| 2017-003933-27 | P3 |
Terminated |
Pneumonia, Bacterial|Pneumonia, Ventilator-Associated |
2019-07-17 |
|
| PRISM-MDR | P3 |
Terminated |
Pneumonia |
2019-07-17 |
71% |
| PRISM-UDR | P3 |
Terminated |
Pneumonia |
2019-07-17 |
71% |